**Index**

Note: page numbers in *italics* refer to figures and tables

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdominal aortic aneurysms</td>
<td>355–63</td>
</tr>
<tr>
<td>Endovascular graft postmarket assessment</td>
<td>358–60</td>
</tr>
<tr>
<td>Endovascular repair</td>
<td>356, 357–8</td>
</tr>
<tr>
<td>Indications for treatment</td>
<td>355–6</td>
</tr>
<tr>
<td>Mortality rate</td>
<td>358, 359</td>
</tr>
<tr>
<td>Natural history</td>
<td>355–6</td>
</tr>
<tr>
<td>Outcomes of treatment</td>
<td>357–8</td>
</tr>
<tr>
<td>Risk:benefit profile</td>
<td>360</td>
</tr>
<tr>
<td>Rupture risk</td>
<td>357</td>
</tr>
<tr>
<td>Stent-grafts</td>
<td>356, 358–63</td>
</tr>
<tr>
<td>Surgery</td>
<td>356, 357</td>
</tr>
<tr>
<td>ABT-578 sirolimus analog</td>
<td>340–1, 343–4</td>
</tr>
<tr>
<td>Acanthamoeba keratitis</td>
<td>433</td>
</tr>
<tr>
<td>Access, equitable to medical devices</td>
<td>376</td>
</tr>
<tr>
<td>Accredited persons</td>
<td>198–9</td>
</tr>
<tr>
<td>Acidemia, metabolic</td>
<td>475</td>
</tr>
<tr>
<td>Acidosis, fetal/infant</td>
<td>471</td>
</tr>
<tr>
<td>Active implantable medical devices (AIMDs)</td>
<td>178–9, 182</td>
</tr>
<tr>
<td>Active medical device</td>
<td>179</td>
</tr>
<tr>
<td>Acupuncture</td>
<td>325–6</td>
</tr>
<tr>
<td>Safety</td>
<td>325</td>
</tr>
<tr>
<td>Acupuncture needles</td>
<td>322–6</td>
</tr>
<tr>
<td>Embedded auricular</td>
<td>325–6</td>
</tr>
<tr>
<td>Manufacturers</td>
<td>324</td>
</tr>
<tr>
<td>Adept Registry for Clinical Evaluation (ARIEL)</td>
<td>110–11</td>
</tr>
<tr>
<td>Adolescence, corrective surgery</td>
<td>209–10</td>
</tr>
<tr>
<td>AdvaMed trade association</td>
<td>194, 200</td>
</tr>
<tr>
<td>Advance Bionics Corporation</td>
<td>396–7</td>
</tr>
<tr>
<td>Adverse event(s)</td>
<td>24, 26</td>
</tr>
<tr>
<td>Reduction</td>
<td>24, 26</td>
</tr>
<tr>
<td>Reports</td>
<td>13</td>
</tr>
<tr>
<td>Industry use</td>
<td>165–6</td>
</tr>
<tr>
<td>Adverse event reporting</td>
<td>11–14</td>
</tr>
<tr>
<td>Data elements</td>
<td>294</td>
</tr>
<tr>
<td>Data management</td>
<td>163</td>
</tr>
<tr>
<td>FDA</td>
<td>160–3</td>
</tr>
<tr>
<td>Healthcare providers</td>
<td>162–3</td>
</tr>
<tr>
<td>Improvement</td>
<td>196</td>
</tr>
<tr>
<td>Industry use of information</td>
<td>165–6</td>
</tr>
<tr>
<td>Information sources</td>
<td>161–2</td>
</tr>
<tr>
<td>Underreporting</td>
<td>50–1, 64, 161–2</td>
</tr>
<tr>
<td>Adverse medical device events (AMDE)</td>
<td>24, 26</td>
</tr>
<tr>
<td>Data collection</td>
<td>57</td>
</tr>
<tr>
<td>Data elements of reports</td>
<td>294</td>
</tr>
<tr>
<td>Estimate production</td>
<td>81–2</td>
</tr>
<tr>
<td>Frequency</td>
<td>36</td>
</tr>
<tr>
<td>Indicators</td>
<td>53–4</td>
</tr>
<tr>
<td>Multiple types</td>
<td>36</td>
</tr>
<tr>
<td>Postmarket studies</td>
<td>155–6</td>
</tr>
<tr>
<td>Public health burden</td>
<td>83–4</td>
</tr>
<tr>
<td>Rates</td>
<td>27</td>
</tr>
<tr>
<td>Records</td>
<td>51</td>
</tr>
<tr>
<td>Registries</td>
<td>52–3</td>
</tr>
<tr>
<td>Reporting</td>
<td>47–8, 49, 50–2</td>
</tr>
<tr>
<td>Enhanced</td>
<td>52</td>
</tr>
<tr>
<td>Surveillance</td>
<td>43–58, 47–8, 49, 50–2, 291–2</td>
</tr>
<tr>
<td>Conditions</td>
<td>54–5</td>
</tr>
<tr>
<td>Program</td>
<td>55–7</td>
</tr>
<tr>
<td>Underreporting</td>
<td>50–1, 64</td>
</tr>
</tbody>
</table>

*Medical Device Epidemiology and Surveillance*  
© 2007 John Wiley & Sons, Ltd  
Edited by S. Lori Brown, Rosalie A. Bright and Dale R. Tavris

Burkholderia cepacia 252
  pediatric patients 251
caged-ball valve 367, 368
cancer, hip implant association 448
carbon dioxide partial pressure detector 251, 252
cardiac catheterization 380
cardiac monitors, electromagnetic interference 296, 298
cardiac pacemakers, electromagnetic interference 303, 304, 306, 308, 310, 311, 312
cardiovascular devices
  aortic valves 367–77
  electromagnetic interference 293, 295–6
cardioverter defibrillators see implantable cardioverter defibrillators
care, standards of 46
case-control studies 37, 435–6
  orthopedic devices 458
cataract 427–8
CE marking 181, 182, 184
 cellular phones, electromagnetic interference 311
Center for Devices and Radiological Health (CDRH) 5
  adverse event report data management 163
  epidemiology program 100
  postmarket surveillance 159
Center for Education and Research on Therapeutics (CERTS) 485
Centers for Disease Control and Prevention (CDC)
  meningitis with cochlear implants 399
  National Center for Health Statistics 115–18
  surveillance systems 104
Centers for Medicare and Medicaid Services (CMS)
  databases 113
  mandated registries 110
ceramics, orthopedic materials 443
cesarean section rate 467
cessation of use 29
children
  clinical studies 204
  device-related disease 251
  meningitis association with cochlear implants 397
  orthopedic devices 207–9
 pediatric medical devices 203–15
  radiation exposure 212
  thermometers 205–6
CLARION cochlear implant models 396–7
Clarke Error Grid 226–7
Class I devices 8, 182
  premarket notification 9, 10
Class II devices 8
  postmarket surveillance 153
  premarket notification 9, 10
  regulatory changes 198–9
  Section 522 studies 154
  tracking 16
Class IIa devices 182
Class IIb devices 182
Class III devices 8, 182
  clinical trial information 10
  cochlear implants 396
  postmarket surveillance 153
  premarket approval application 9–10
  premarket notification 9
  regulatory changes 198–9
  Section 522 studies 154
  tracking 16
classification of medical devices 8, 91
  Europe 182–3
cleaning
  bronchoscopes 242–3
  endoscopes 243
clinical data 10
clinical epidemiologic studies 138–40
clinical research studies 127
clinical studies 150–2
  children 204
  design 151–2
clinical trials
  information for premarket notification 10
  premarket 483–4
  cobalt–chrome alloys 441, 442
  cochlear implants 13, 395–405
  DC current leakage 403, 404
  device failures 401, 402–4
  Good Manufacturing Practice 401–2
  hazard evaluation 402–4
  hermeticity failures 401, 402–4
  intended use 395–6
  investigations 397–400
  manufacturer Complaint Report Database 403–4
cochlear implants (continued)
material failure 275
meningitis association 396–404
patient harm assessment 404
positioner component 400, 401
recommendations 400–1
tissue reactions 277
codes
product 91
unique 54, 90, 485
see also product coding systems
cohort studies 36–7
collagen plug sealant devices 381–2, 388, 389–90
COMBI 40+ cochlear implant 401
Common Rule 141
Competent Authorities (CAs) 183, 184, 185
Complaint Report Database 403–4
complementary medical devices see alternative and complementary medical devices
complex devices 29
human factors 31
complex multi-device situations 29–30
computed tomography (CT), pediatric 212
computerization, confidentiality 141–2
Concept Permanence 90
condition of approval (CoA) studies 154, 155, 164
c confidentiality
computerization 141–2
databases 119
violation in published reports 166
Conformity Assessment Bodies (CABs) 181, 188–9
confounding by indication 276
congenital anomalies, breast implants 416
Congressional Black Caucus (US Congress) 195
connective tissue disease, breast implants 420–1
consensus standards, national/international 7
consumer guides 196
Consumer Product Safety Commission (CPSC) 103
consumer protection 6
consumers 187–200
accomplishments 199–200
concerns 193–7
manufacturers 193–4
regulatory safeguards 194–5
safety of implants 195–7
legislative change requests 198–9
organizations 188
regulatory change requests 198–9
regulatory mechanism recommendations 197–9
contact lenses 274, 427
case-control studies 435–6
continuous wear 437
corneal ulcers 430–7
daily wear 432
extended wear 432, 434, 435
hyperpermeable 434
pre-/post-approval studies 434
relative risk 434–5
tissue reaction 278
Continuous Glucose Monitoring System (CGMS) 225–8, 231
continuous subcutaneous insulin perfusion (CSII) 220, 223–4
disadvantages 224–5
contrast medium-related malaria 250–1, 252
controlled medical vocabulary 90
corneal scarring 431
corneal transplant, prion disease transmission 261–2
corneal ulcers
contact lenses 430–7
infectious/non-infectious 436–7
coronary stents, bare metal 337–8, 346
coronary stents, drug-eluting 335–50
antiproliferative agents 336–42, 343–4
biocompatible coatings 336
comparative trials 342, 345
complex coronary lesions 345–6
postapproval requirements 346–7
postmarket adverse events 348–50
regulation 346–50
safety 346
corrections 17–18
cosmetic surgery
adolescence 210
see also breast implants, augmentation
Cosmetic Surgery National Data Bank 108
Cosmetic Surgery Telephone Survey 107
Council for International Organizations of Medical Sciences (CIOMS) guidelines 135, 141
Creutzfeldt–Jakob disease (CJD) 259
iatrogenic transmission 260–1
new variant 259, 260
surgical instrument transmission 260–1, 262, 263, 264, 265, 267
transplant tissue transmission 262
critical care areas 32, 34
cupping 324

Dalkon Shield 189, 190
Danish Hip Arthroplasty Register 447
Danish Registry for Plastic Surgery of the Breast 111–12, 192
data
  collection 105
  event recovery 165
  elements of adverse event reports 294
  insurance claims 173
  management and adverse event reporting 163
  national surveys 115–18
  sources 99–120
  submission from manufacturers 197
  see also registries
data mining 119, 167
databases 100–1
  academic 115
  adverse event reporting 162
  automated large administrative 112–15
  Complaint Report 403–4
  confidentiality 119
  European 184, 185
  growing capabilities 119
  privacy issues 119
  private healthcare 113
  surveillance 101–4
  technology assessment 118
  use in epidemiology studies 140–2
  see also named databases
dawn phenomenon 224
Declaration of Geneva 128
Declaration of Helsinki 128
decontamination of surgical instruments 263–5, 266–7, 267
defibrillators
  external 296
  see also implantable cardioverter defibrillators
Device Experience Network (DEN) database
  see Medical Device Reporting (MDR) database
Device Safety-Exchange (DS-X) 70, 72
device use 32
DeviceNet
  design 64, 65–6, 67–8
  implementation 68
di-2-ethylhexylphthalate (DEHP) 211
diabetes mellitus
  control 227
  devices used in management 219–31
diabetic ketoacidosis (DKA) 225, 230
diabetic neuropathy, magnet therapy 329–30
diagnosis codes 26
Dialysis Surveillance Network 104
diseases
  breast pump-related 248, 249
  bronchoscope-related 239, 240–1, 242–3
  endoscope-related 240–1, 243–4
  hemodialysis-related 244, 245, 246–7
  medical device-related 237–53
  needle-related 250
  neonatal/pediatric intensive care unit outbreaks 247–50
  prevention 24, 25
  syringe-related 250
  tongue depressor-related 248, 250
  treatment 24, 25
  ventilator-related outbreaks 248–50
disinfection
  bronchoscopes 242–3
  endoscopes 243
  surgical instruments 263–5, 266–7, 267
  disk valve 368
documentation, device use 32, 53, 55, 57, 76
Drug Safety Oversight Board 167–8
Duett sealing device 381, 382
dura mater transplantation 264
Dynamic Registry 109
ear candles 326–8
  complications 327–8
ear infections 206–7
EC declaration of conformity 181
economics of medical devices 148
effectiveness checks 18
elderly patients
  aortic valve replacement 371–2
  hip implants 450–1
  intraocular lenses 429
electrical acupuncture point detector 324
electro-acupuncture stimulator 323, 326
electrocardiography (ECG), fetal waveform monitoring 473–6
emblematic compatibility 292
emblematic interference with medical devices 291–316
cardiovascular devices 293, 295–6
cases 311–13
coding problems 314, 315
deaths 303, 306–7
device types 303
FDA reports 297–316
implantable cardioverter defibrillators 303, 304–5
MRI devices 298, 305, 308–9, 310
other medical devices 312
reports 298, 299, 300–5
sources 303, 305, 309
statistical procedures 297–8
tip-of-the-iceberg paradigm 314, 315
electronic fetal monitoring (EFM) 464–70
antepartum surveillance 469
device 465–6
fetal ECG waveform monitoring 473–6
intervention
rate 477
risk for fetal distress 472–3
methodology 468–9
nonreassuring fetal heart rate patterns 472–3
studies 466–8
surveillance parameters 477
technical difficulties 469–70
electronic muscle stimulators 320, 321, 322
Emergency Care Research Institute (ECRI),
technology assessment databases 118, 167
emergency departments, NEISS 79–80, 81, 83, 103–4
endoscopes, GI 240–1, 243–4
endotoxins, hemodialysis-related 244, 245, 246
enforcement activities 15–18
environmental factors 30
epidemiology 1, 2, 3, 21–38
ethical guidelines 134
importance 24, 26
epidemiology studies
clinical 138–40
data sources 99–120
database use 140–2
descriptive 35–6
design 35–7
cultural features 32
device features 26–32, 33–4
intrinsic features 28–32
regulatory features 27–8
ethical requirements 136–42
heart valve replacement 373–6
independent review 139–40
informed consent 140
materials for devices 273–6, 277–8, 278
medical records use 140–2
postmarket 156
respect for subjects 140
survey use 140–2
epinephrine, acute poisoning 311–12
essential requirements (EU) 180
ethic(s) 127–42
ethical codes 128
ethical guidelines
epidemiologic 134
professional 133–6
requirements for epidemiology studies 136–42
ethnic differences 195
EUDAMED database 184, 185
European Economic Area (EEA), regulation of medical devices 93
European Union (EU) 177–85
classification of medical devices 182–3
consumer issues 188–9
harmonization process 180, 188–9
medical device groups 178
Member States Competent Authorities 183, 184, 185
regulation of medical devices 93
traceability of medical devices 184
vigilance system 184–5
event recovery data 165
Everolimus 341, 344
experts, internal 13
exports of medical devices 148, 149
exposure to devices 32
failure of device, reporting 48
Fair Access to Clinical Trials Act (2005) 168
FDA Modernization Act (1997) 162
femoral artery catheterization site complications 388
hemorrhage 383, 384–5
postprocedure hemostasis 379
femoral head, aseptic necrosis 444
fetal distress in labor 467
intervention risk 472–3
operative deliveries 474
fetal ECG waveform monitoring 473–6
fetal monitoring, intrapartum 463–78
epidemiological assessment 466–8
modalities 476–8
fetal pulse oximetry 471–3
fetus
blood gas analysis 470–1
see also electronic fetal monitoring (EFM); heart rate, fetal
Fibroid Registry for Outcomes Data (FIBROID) registry 108
fibromyalgia 420, 421
field inspections 17–18
Finnish Arthroplasty Registry 112
fixation devices 208, 209
fomites 238
Food, Drug and Cosmetics Act 164
see also Section 522
Food and Drug Administration (FDA) 5
academic opportunities 167–8
adverse event reporting 160–3
breast implant regulation 409–11
surveillance 411–21
BSE transmission risk minimization 267–8
causality assessment 13–14
cochlear implant investigations 397–400
contact lens regulation 431
corrections 17–18
data mining 119, 167
database of device adverse events 12
diabetes device regulation 221
drug-eluting coronary stent regulation 346–7
em electromagnetic interference reports 297–316
guidance 7–8
heart valve replacement guidance 372
hemostasis device evaluation 387–9
postmarket performance 382–7
safety study 389–90
human subjects protection regulations 131–2, 133
intraocular lens regulation 428–30
MED-EL cochlear implant recommendations 404
NEISS long-term applications 84
passive reporting system 95
pediatric medical devices 213–14
postmarket tools 11–15, 199–200
publications 166, 167
regulation of medical devices 93
regulatory controls 6, 194–5
removals 17–18
responsibility 6
scientific article writing 166
stent-graft postmarket assessment 358–60
surveillance program 45
surveillance systems 101–3
tools 46–7
tracking program 16–17
see also Medical Device Reporting (MDR) database
Food and Drug Modernization Act (1997) 68
fractures, children 208, 209
General and Plastic Surgery Devices Panel 410
general controls 6–7
general medical devices 178, 182
glargin 224
Global Harmonization Task Force (GHTF) 103
Global Medical Device Nomenclature (GMDN) 92
gloves, medical 273
latex 279–82, 283–5, 285–6
sensitivity 278
starch peritonitis 251, 252
tissue reactions 277
glucose
blood level control 220, 224, 229
continuous monitoring devices 225–8
fluctuations 229
Glucowatch biographer 226, 227, 231
Good Clinical Practice (GCP) guidelines 133
Good Manufacturing Practice (GMP), cochlear implants 401–2
government agencies databases 113–14
government regulatory agencies 196, 198
Gram-negative bacteria, hemodialysis-related outbreak 245, 246
INDEX

494

grommets 206–7
growth plates, mechanical 209
gynecomastia 210–11

Health and Human Services Department (HHS, US) 128, 129–30
human subject protection regulatory requirements 130–1, 132, 133
Health Insurance Portability and Accountability Act (1996) 141
health regulatory agencies 198
Health Risk Assessment (HRA), cochlear implant failures 403
Healthcare Cost and Utilization Project (HCUP) 114
healthcare institutions, device management 94
healthcare providers
adverse event reporting 162–3
statistical samples 57
heart rate, fetal 463–4
abnormal rhythms 466
analysis 474
decelerations 477
electronic monitoring 464–70
nomenclature for tracings 469
nonreassuring pattern 471–2, 476
patterns 468, 469, 477
rhythm 465–6
technical difficulties 469–70
heart valves
access issues 376
adverse event reports 373
allograft 369–70
animal tissue 369
anticoagulant therapy 369
autograft 369
bio-prosthetic 369–70
complications of replacement 373–5
device reprogramming 375–6
epidemiological studies for replacement 373–6
failure 275
FDA guidance for replacement 372
homograft 369–70
human tissue 369–70
mechanical 367–9
objective performance criteria for replacement 372
patient tracking 375–6
tissue 369–70
tissue reaction 278
see also aortic valves
hemodialysis
disease outbreaks 244, 245, 246–7
membrane materials 274, 277, 278
hemoglobin A1c (HbA1C) levels 226, 227, 229
testing 220
hemostasis, postprocedure of femoral artery 379
hemostasis devices 379–91
adverse events 37, 382–7, 388–9
collagen plug sealant devices 381–2, 388, 389–90
 complication rates 388
FDA study 387–9
femoral artery hemorrhage 383, 384–5
gender differences 383–5
hematoma 383, 384–5
infection 383
meta-analyses 386–7
non-invasive patches 382
postmarket performance 382–7
protective effects 389
registry studies 37
risk evaluation study 387–9
safety assessment study 389–90
safety issues 386–7
suture 380–1, 388
types 380–2
women relative risk 383–5
hepatitis B
hemodialysis-related outbreak 245, 246–7
needle-related 250, 252
hernia repair 210
hip arthroplasty, total 444–5
complications 447–8
device survival 446–7
operative mortality 445–6
rates 451
hip implants
adverse event reports 448–50
cancer association 448
complications 447–8
costs 451
elderly patients 450–1
heterotopic ossification 448
methodological issues 457–8
rates 451
retrieval analysis 447–8
revision 447–8
risk factors 444–5
study design 457–8
thromboembolism 447–8
trends 450–1
wear rates 447
hip prostheses 274, 442
tissue reaction 278
HIV infection
hemodialysis-related outbreak 244, 245
needle-related 250
hospitals, surveillance systems 175
human factors 30–1
surveillance studies 48
human subjects
information 141
informed consent 132, 133
protection 127–8
regulations 129–30, 131–2, 133
regulatory requirements 130–1
respect for 140
hybrid studies 37
hyperglycemia 225, 230
hypodermic needles, disease
outbreaks 250
hypoglycemia 225
control 228
insulin pumps 224
hypothesis-testing studies 36–7
identifier, unique 54, 90, 485
implantable cardioverter defibrillators 24
electromagnetic interference 298, 303, 304–5, 311, 312
registry 106
tracking 16–17
in vitro diagnostic medical devices (IVDs) 178, 179, 182–3
Independent Review Boards (IRB) 137–8
epidemiology studies 139–40
Industrial Epidemiology Forum (IEF) guidelines 134–5
industry, use of information for adverse event reports 165–6
infants
acidosis 471
blood gas analysis 470–1
seizures 467
infections
breast implants 414
hemostasis devices 383
late-onset 208
information
industry use from adverse event reports 165–6
research participants 141
sources for adverse event reporting 161–2
informed consent 132, 133
epidemiology studies 140
infusion pumps, external 223–5
inguinal hernia 210
Institute of Medicine (IOM), pediatric medical devices 213–14
insulin 219–20
closed loop systems 230–1
concentrated 230
delivery devices 221–5
external infusion pumps 223–5
implantable pumps 228–30
jet injectors 222–3
long-acting 224
pen device 221–2
sensors 231
therapy 220
insurance claims data 173
International Epidemiologic Association (IEA) guidelines 135
International Society for Environmental Epidemiology (ISEE) guidelines 135
international vigilance surveillance system 103
intervertebral disc, degenerative disease 452–3
intervertebral disc replacement 452–6
effectiveness 454–6
implant survivability 454
methodological issues 457–8
patient factors 455
patient outcome 454–5
perioperative complications 455–6
radiographic assessment 455
safety assessment 454–6
study design 457–8
surgical risk 455
intraocular lenses 427
access issues 376
epidemiology 427–30
outcomes 428–9, 430
younger patients 429–30
intrauterine contraceptive device (IUD) 189
Investigational Device Exemption (IDE) regulation 137
investigational plans 151
jet injectors 222–3
disease outbreaks 250, 252
joint replacement costs 451
justice principle 129–30
keratitis, microbial 431–2, 433–5, 436–7
Kids’ Inpatient Database (KID) 114
Klebsiella oxytaca related outbreaks 248, 249
Klebsiella pneumoniae, hemodialysis-related outbreak 244, 245
kuru 259
labeling 6, 10
requirements 46
labor
fetal distress 467
long 477–8
lasers 187
latex allergy 280, 281, 282, 283–5, 285–6
latex gloves 279–82, 283–5, 285–6
sensitivity 278
starch peritonitis 251, 252
legislation
change and consumer requests 198–9
pediatric medical devices 213–14
liposuction
disease outbreak 252
ultrasound-assisted 210–11
listing 6
literature review 171–3
long-term implantable insulin pump (LIIP) 228–30
lumbar disc degeneration 453
magnet therapy 328–31
magnetic resonance imaging (MRI)
electromagnetic interference 298, 305, 308–9, 310
embedded auricular needles 325–6
malaria, contrast medium-related 250–1, 252
mammography, breast implants 414–15, 417
mammoplasty, re-operations 419–20
manual compression 379
hemostasis device comparison 386
Manufacturer and User Facility Device Experience Database (MAUDE) 101–2, 162, 291–2
breast implant surveillance 411, 412, 415
cochlear implant investigations 398
electromagnetic interference reports 296, 297, 311
intraocular lenses 430
problem codes 313–14
reports 292–3
manufacturers
acupuncture needles 324
ADME reports 293, 301–2
Complaint Report Database 403–4
consumer concerns 193–4, 197
data submission 197
drug-eluting coronary stent regulation 347
ear candles 326–7
inspections 13
use of information for adverse event reports 165–6
manufacturing practices 7
market for medical devices 147–8
export 148, 149
growth potential 148
market surveillance, European 183
marketing applications 8–10
materials for devices 32, 273–86
epidemiology 276, 278
failures 275
surveillance 276, 278
tissue reactions 276, 277–8
see also latex allergy
MED-EL cochlear implants 401, 402–4
Medical Device Reporting (MDR) database
breast implant surveillance 411
intraocular lenses 430
postmarketing studies 155
surveillance 291
Medical Device Reporting (MDR) system 81
adverse event reports 484
hip implant reports 448–50
regulation 12
Medical Device User Fee and Modernization Act (2002) 198–9, 203, 213
medical devices
definition 1–2, 5–6, 22–3
EU 178–9
incremental changes 484
scope 71
terminology 27
Medical Product Surveillance/Safety Network (MedSun) 52, 63–76, 103
adverse event reporting 162–3, 484
current status 71–4
design 69–70, 71
enhanced reporting 52
epidemiology 75–6
facilities 72–3, 76
feedback 70
networks 74
postmarketing surveillance 485
reports 71–2, 73
safe use promotion 74–5
surveillance 54
training 70
underreporting 51
medical records, use in epidemiology studies 140–2
MedWatch 56–7, 162, 291
meningitis, incidence 401
meningitis with cochlear implants 396–404
epidemiology 399–400
FDA response 397–401
mercury amalgam tooth fillings, tissue reaction 278
metabolic acidemia prediction 475
metals, orthopedic devices 441–3
_Mycobacterium mesophiticum_, bronchoscope-related outbreak 240, 242
microbial keratitis 431–2, 433–5, 436–7
milk contamination 248, 249
MiniMed Continuous Glucose Monitoring System 225–8, 231
mobile phones, electromagnetic interference 311
monitoring of devices 44, 46
moxibustion 322, 324
Multi-Item Gamma Position Shrinker (MGPS) 119
multiple daily insulin (MDI) 220
Mutual Recognition Agreements (MRAs) 181
_Mycobacterium chelonae_, bronchoscope-related outbreak 240–1, 242
_Mycobacterium tuberculosis_, bronchoscope-related outbreak 239, 240–1, 242
naming of devices 88–9
National Center for Health Statistics 115–18
National Clearinghouse of Plastic Surgery Statistics 107
National Drug Code (NDC) 173, 174
Directory 94
National Electronic Injury Surveillance System (NEISS) 54, 67, 79–84, 103–4
data collection/analysis 81–2
limitations 81
long-term applications 84
medical device surveillance utilization 83–4
medical device-associated adverse event estimates 81–2
non-sampling errors 81
postmarketing surveillance 485
sampling errors 81
uses 80–1
National Eyecare Outcome Network (NEON) database 429–30
National Health Interview Survey 115
National Healthcare Survey (NHCS) 117
National Home and Hospice Care Survey (NHHCS) 117–18
National ICD Registry 106
National Institutes of Health (NIH) registries 108–10
National Maternal and Infant Health Survey (NMIHS, 1998) 116
National Medical Association 195
National Mortality Followback Survey (1993) 115–16
National Nosocomial Infections Surveillance Systems (NNIS) 104
National Research Center (NRC) for Women and Families 188, 195
Nationwide Inpatient Sample (NIS) 114
eonatal intensive care unit, disease outbreaks 247–50
neurological instruments, CJD transmission 260–1
New Approach concept (EU) 178, 179–81
New Approaches to Coronary Interventions registry 108–9
nomenclature of medical devices 87–96
applications 93–5
attributes 90
commercial applications 94
current terminologies 91–2
nomenclature of medical devices (continued)
definition 90
epidemiology of devices 94–5
hierarchies 89
management of devices 94
naming of devices 88–9
quality indicator 90
relationship supporting 89–90
relationships of devices 90
specificity level of devices 88–9
surveillance of devices 94–5
technical elements 87–90
UMDNS™ 91–2
non-significant risk device study 137–8
Notified Bodies 180–1
Nuremberg Code 128

obesity, osteoarthritis risk 444
objective performance criteria, heart valve replacement 372
Office of Device Evaluation 163
cochlear implants 402
Office of Surveillance and Biometrics (OSB) 164
operating rooms 32, 33
operator error see user error
ophthalmic devices 427–38
ORA inspection, cochlear implants 401–2
orthopedic devices 207–9, 441–59
data sources 456–7
effectiveness 458
intervertebral disc replacement 452–6
materials 441–4
methodological issues 457–8
safety 458
study design 457–8
ossification, heterotopic 448
osteoarthritis
hip 444
spine 452–3
otitis media with effusion 206–7
oximetry, fetal pulse 471–3

pacemakers see cardiac pacemakers
paclitaxel, drug-eluting coronary stents 338–40, 341–2, 343, 344
postmarket adverse events 349
pain, magnet therapy 329, 330–1
pancreas, artificial mechanical 230–1
patches, non-invasive 382
Patient and Consumer Coalition 196
patient tracking, heart valves 375–6
pediatric intensive care units, disease outbreaks 247–50
pediatric medical devices 203–15
regulatory framework 212–14
peer review 166
Perclose devices 380–1, 382, 387
percutaneous coronary intervention
manual compression 379
stenting 335–6
performance failure of devices 160
pharmacoepidemiology 171–5
pharmacy reimbursement 173
Plasmodium falciparum, contrast medium-related 250–1, 252
polyethylene 443
ultra-high molecular weight 443
polymers, orthopedic materials 443–4
polymethylmethacrylate (PMMA) 443–4
polyurethane breakdown products 278
post-approval studies 46, 197
postmarket condition of approval studies 163–5
postmarket enforcement 15–18
postmarket oversight 2, 3, 10–18
clinical data 10
postmarket performance, hemostasis devices 382–7
postmarket studies 148, 152–6
adverse event reports 155–6
condition of approval 154, 155, 164
consumer advocates 196–7
epidemiologic 156
follow-up 152–3
mandated 14–15
Medical Device Reporting 155
Section 522 154–5, 164–5
postmarket surveillance 2, 11–15, 46, 483–5
academic perspective 159–68
Europe 183
program 484–5
studies 47, 153
preclinical studies 148, 149–50
premarket agreements 197
premarket application 9–10
clinical data 10, 11
conditions of approval 14
Pre-Market Approval (PMA) process
application 9–10
cochlear implants 396
diabetes device regulation 221
premarket notification 7, 9
premarket review 6–8
premarket studies 46, 148–53
premarket submissions, pediatric devices 212–13
pressure-equalizing tubes 206–7
prevention options 24, 25
prions 259–68
iatrogenic transmission 260–1
medical devices with tissue component 264–5, 266–7, 267
proteins 260
transplant tissue transmission 261–2
privacy, databases 119
Privacy Rule 141
private healthcare databases 113
procedure codes 32
reimbursement 174
product codes 91
product coding systems 28, 50, 54, 55, 76
identification 28
unique codes 54, 90, 485
product development protocol (PDP) 9
product life cycle 148–53
product problem reporting 11–14
product recall 165
proplast TMJ implants 193
prostheses, implanted 23
Prosthetic Titanium Rib implant 209
Pseudomonas aeruginosa 253
bronchoscope-related 243
Pseudomonas cepacia 253
public health 6
burden of adverse events 83–4
disease outbreaks 238
epidemiologic studies 100
interventions 75–6
notifications 13
publications 166, 167
pulsed magnetic fields 328–31
pyrogenic reactions, hemodialysis-related 244, 245, 246
Quality Systems regulation 6, 7, 14, 46
cochlear implants 401–2
QuickSeal Arterial Closure System 382
racial differences 195
racial issues, access to medical devices 376
radiation exposure, children 212
rapamycin, drug-eluting coronary stents 336–8
recall of device 197–8
authority 17–18
mandatory order 18
records 7
registration 6
registries 52–3, 105–12
breast implants 192
data collection 105
design 105
government-sponsored 108–12
hip implant data 447
manufacturer-sponsored 110–11
national form other countries 111–12
sponsored by professional organizations 106–8
regulation of medical devices
change and consumer requests 198–9
consumer concerns 194–5, 197–200
pediatric 212–14
US 5–18, 93
removals 17–18
reporting 64
barriers 47–8, 49
data elements 102
mandatory 102
voluntary 56–7
see also adverse event reporting; adverse medical device events (AMDE), reporting
reports 7
annual 46
incompleteness 48, 50
MedSun 71–2, 73
see also adverse event(s), reports
respect for persons 129
re-use of devices 29
surveillance studies 48
Rhizopus microsporus 248, 250, 253
risk to health, definition 17
risk:benefit ratio, favorable 139
rods, spinal 209
Royal College of Physicians of London, ethical code 128
rubber, natural 280

Safe Medical Devices Act (1990) 64, 102, 161
safe use promotion 74–5
safety
  alert 165
  children 211–12
  long-term 195–7
  surveillance 95
saline-filled breast implants 409, 414
rupture 417
scalp blood gas analysis 470–1
scientific articles, peer review 166
scoliosis
  congenital 208, 209
  repair 209–10
Section 522 studies 164–5
  postmarket 154–5
seizures, infants 467
sensors, insulin 231
Serratia marcescens 253
significant risk device study 137–8
silicone
  extracapsular 417, 420
  TMJ implants 192
silicone gel breast implants 191–2, 407–22
  adverse event reports 412–14
  coding of adverse events 413–14
  fibromyalgia 420, 421
  infections 414
  moratorium 410
  rupture 413, 416–19
  silent 417
tissue reaction 278
sirolimus
  adverse events 346
  drug-eluting coronary stents 336–8, 343–4, 346
  postmarket adverse events 348–9
Society of Thoracic Surgeons (STS) National Adult Cardiac Surgery Registry 106–7
soybean oil, breast implants 408
special controls 7–8
specificity level of devices 88–9
Staphylococcus paucimobilis outbreaks 248, 249
spinal cord stimulator, electromagnetic interference 303, 304, 308, 310, 311, 312–13
spinal fusion 209
spinal growing rods 209
spinal osteoarthritis 452–3
spinal surgery
  arthrodesis 453
  pediatric 208–9
  risk factors 452
ST waveform analysis 474
stainless steel 441, 442
STAN fetal heart monitor 474, 475–6, 477
standards development organizations (SDOs) 7
starch peritonitis 251, 252
Starr–Edwards caged-ball valve 367, 368
stent-grafts
  abdominal aortic aneurysms 356, 357–63
  attachment 362
  delivery 361
  design 361–3
  mortality rate 358, 359
  patency 363
  performance 361–3
  postmarket assessment 358–60
  structure 362
stents see coronary stents
sterilization, surgical instruments 263–5, 266–7, 267
Streptococcus pneumoniae, meningitis
  association with cochlear implants 397, 399
surgical instruments
  CJD transmission 260–1, 263, 264, 265, 267
decontamination 263–5, 266–7, 267
  peripheral tissues 262
  prion disease transmission 260–1, 262
surveillance 1, 2, 3
  active 53–4
  AMDE 43–58
  reports 47–8, 49, 50–2
  conditions 54–5
data collection 57
goals 44, 45
  rationale 44, 45, 46–7
  registries 52–3
  statistically-based program 57
systems 64, 65–6, 67
  hospitals 175
<table>
<thead>
<tr>
<th>Technique Improvement</th>
<th>umbilical cord blood gas analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>tools</td>
<td>470–1</td>
</tr>
<tr>
<td>Surveys</td>
<td>umbilical hernia 210</td>
</tr>
<tr>
<td>national 115–18</td>
<td>underreporting 50–1, 64, 161–2</td>
</tr>
<tr>
<td>use in epidemiology studies 140–2</td>
<td>Unique Medical Device Identification Code</td>
</tr>
<tr>
<td>Suture hemostasis devices 380–1, 388</td>
<td>54, 90, 485</td>
</tr>
<tr>
<td>Syringes, disease outbreaks 250</td>
<td>Universal Medical Device Nomenclature System™ (UMDNS™) 91–2</td>
</tr>
<tr>
<td>Tampons 189–91</td>
<td>universal precautions 280</td>
</tr>
<tr>
<td>Technology Management 94</td>
<td>user error</td>
</tr>
<tr>
<td>Teflon TMJ implants 192</td>
<td>avoidance 146–7</td>
</tr>
<tr>
<td>Telemetry system, electromagnetic interference 303, 306, 307</td>
<td>reporting 48</td>
</tr>
<tr>
<td>Temperature-taking devices 205–6</td>
<td>safety of devices 484</td>
</tr>
<tr>
<td>Temporomandibular joint (TMJ) implants 192–3</td>
<td>user-related error 48, 49</td>
</tr>
<tr>
<td>Terminologies, current 91–2</td>
<td>uterine contraction detection 466</td>
</tr>
<tr>
<td>Thermometers 205–6</td>
<td>valid scientific evidence concept 10</td>
</tr>
<tr>
<td>Thromboembolism, hip implants 447–8</td>
<td>validity of epidemiology studies 139</td>
</tr>
<tr>
<td>Tissue components of medical devices 264–5, 266–7, 267</td>
<td>value of epidemiology studies 139</td>
</tr>
<tr>
<td>Tissue reactions, materials for devices 276, 277–8</td>
<td>Vasoseal 387, 390</td>
</tr>
<tr>
<td>Titanium alloys 441, 443</td>
<td>venous catheters, tissue reactions 277</td>
</tr>
<tr>
<td>Tongue depressors 248, 250, 253</td>
<td>ventilators 31</td>
</tr>
<tr>
<td>Tooth fillings, tissue reaction 278</td>
<td>disease outbreaks 248–50</td>
</tr>
<tr>
<td>Total Product Life Cycle (TPLC) program 163–4</td>
<td>electromagnetic interference 305</td>
</tr>
<tr>
<td>Toxic shock syndrome 190–1</td>
<td>vigilance system 184–5</td>
</tr>
<tr>
<td>Traceability of medical devices 184</td>
<td>webVDME™ 119</td>
</tr>
<tr>
<td>Tracking 16–17</td>
<td>World Health Organization (WHO), Good Clinical Practice guidelines 133</td>
</tr>
<tr>
<td>Transplant tissues, prion disease transmission 261–2</td>
<td>World Medical Association, Declaration of Helsinki 128</td>
</tr>
<tr>
<td>Treatment options 24, 25</td>
<td>Zotoralimus 340–1, 343–4</td>
</tr>
<tr>
<td>Trilucent breast implant 408</td>
<td></td>
</tr>
<tr>
<td>Tympanostome tubes 206–7</td>
<td></td>
</tr>
</tbody>
</table>